Table 2.
Univariable regression analysis of clinicopathological parameters for the prediction of survival outcomes in UTUC patients.
| Variables | Overall survival | Cancer-specific survival | Disease recurrence-free survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | P | |
| Age (>67 years vs ≤67 years) | 1.034 | 0.807–1.325 | 0.789 | 0.944 | 0.716–1.245 | 0.683 | 0.945 | 0.750–1.190 | 0.629 |
| Sex (Male vs Female) | 0.891 | 0.695–1.143 | 0.364 | 0.828 | 0.628–1.093 | 0.183 | 0.869 | 0.689–1.095 | 0.235 |
| Smoking (yes vs no) | 0.904 | 0.681–1.199 | 0.483 | 0.851 | 0.618–1.172 | 0.324 | 0.885 | 0.680–1.152 | 0.364 |
| Tumor site | 0.818 | 0.738 | 0.667 | ||||||
| Pelvicalyceal | 1.000 | Reference | 1.000 | Reference | 1.000 | Reference | |||
| Ureteric | 0.941 | 0.702–1.260 | 0.683 | 1.008 | 0.731–1.392 | 0.959 | 0.945 | 0.720–1.241 | 0.686 |
| Both | 1.064 | 0.753–1.503 | 0.724 | 1.157 | 0.793–1.688 | 0.448 | 1.112 | 0.809–1.529 | 0.512 |
| Tumour stage | <0.001 | <0.001 | <0.001 | ||||||
| Tis, Ta, T1 | 1.000 | Reference | 1.000 | Reference | 1.000 | Reference | |||
| T2 vs Tis, Ta, T1 | 1.659 | 1.041–2.644 | 0.033 | 1.716 | 0.990–2.974 | 0.054 | 1.518 | 1.008–2.284 | 0.046 |
| T3 vs Tis, Ta, T1 | 3.572 | 2.428–5.255 | <0.001 | 4.054 | 2.579–6.374 | <0.001 | 3.022 | 2.152–4.245 | <0.001 |
| T4 vs Tis, Ta, T1 | 8.725 | 5.788–13.156 | <0.001 | 10.558 | 6.581–16.939 | <0.001 | 7.451 | 5.142–10.798 | <0.001 |
| Tumor grade (high vs low) | 3.104 | 2.141–4.501 | <0.001 | 3.835 | 2.440–6.029 | <0.001 | 2.409 | 1.757–3.303 | <0.001 |
| Lymph node status | <0.001 | <0.001 | <0.001 | ||||||
| pN0 | 1.000 | Reference | 1.000 | Reference | 1.000 | Reference | |||
| pNx vs pN0 | 1.484 | 0.960–2.295 | 0.076 | 1.498 | 0.904–2.482 | 0.117 | 1.496 | 1.001–2.237 | 0.050 |
| pN + vs pN0 | 5.318 | 3.222–8.776 | <0.001 | 6.055 | 3.452–10.621 | <0.001 | 5.512 | 3.453–8.797 | <0.001 |
| LVI (positive vs negative) | 2.628 | 1.970–3.507 | <0.001 | 2.843 | 2.074–3.896 | <0.001 | 2.309 | 1.750–3.047 | <0.001 |
| CVH (With vs Without) | 2.176 | 1.671–2.833 | <0.001 | 2.375 | 1.775–3.178 | <0.001 | 1.997 | 1.554–2.565 | <0.001 |
| CKD4–5 vs CKD1–3 | 1.727 | 0.987–3.019 | 0.055 | 1.447 | 0.741–2.824 | 0.279 | 1.417 | 0.812–2.472 | 0.219 |
| Size (>3 cm vs ≤3 cm) | 2.008 | 1.502–2.685 | <0.001 | 2.054 | 1.481–2.850 | <0.001 | 1.871 | 1.435–2.441 | <0.001 |
| Margin status (positive vs negative) | 2.251 | 1.536–3.299 | <0.001 | 2.426 | 1.606–3.665 | <0.001 | 1.979 | 1.362–2.875 | <0.001 |
| Multifocality (present vs absent) | 0.929 | 0.658–1.313 | 0.677 | 1.008 | 0.694–1.464 | 0.967 | 0.957 | 0.696–1.316 | 0.789 |
| Surgical approach (laparoscopic vs open) | 0.726 | 0.540–0.974 | 0.033 | 0.675 | 0.487–0.936 | 0.019 | 0.877 | 0.676–1.138 | 0.323 |
| Tumor side (right vs left) | 1.062 | 0.829–1.360 | 0.635 | 1.098 | 0.833–1.448 | 0.507 | 1.069 | 0.848–1.346 | 0.573 |
| AAPR (<0.58 VS ≥0.58) | 1.823 | 1.374–2.419 | <0.001 | 2.026 | 1.464–2.803 | <0.001 | 1.550 | 1.202–1.999 | 0.001 |
| Anemia (Yes vs No) | 2.012 | 1.570–2.578 | <0.001 | 2.067 | 1.567–2.728 | <0.001 | 1.684 | 1.336–2.122 | <0.001 |
| Adjuvant therapy (yes vs no) | 0.873 | 0.680–1.120 | 0.286 | 0.931 | 0.706–1.230 | 0.616 | 1.111 | 0.882–1.400 | 0.371 |
*Note: AAPR: Albumin-to-Alkaline Phosphatase Ratio; CVH, concomitant variant histology; LVI, lymphovascular invasion; RNU, radical nephroureterectomy.